Long-term efficacy of leptin replacement in patients with familial partial lipodystrophy, Dunnigan variety (FPLD)

被引：0
|
作者：
Park, Jeany
Javor, Edward D.
Cochran, Elaine K.
Depaoli, Alex M.
Gorden, Phillip
机构：
来源：
DIABETES | 2006年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A18 / A18
页数：1
相关论文
共 50 条
  • [31] What is the diagnosis? The patient was clinically diagnosed with familial lipodystrophy associated with the metabolic syndrome. Genetic studies confirmed the presence of type 2 familial partial lipodystrophy syndrome of the Dunnigan variety
    Kannan, Subramanian
    Khanna, Ila
    Kaur, Manmeet
    Radin, Michael
    ENDOCRINE PRACTICE, 2011, 17 (04) : 665 - 665
  • [32] Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy
    Elif A. Oral
    Phillip Gorden
    Elaine Cochran
    David Araújo-Vilar
    David B. Savage
    Alison Long
    Gregory Fine
    Taylor Salinardi
    Rebecca J. Brown
    Endocrine, 2019, 64 : 500 - 511
  • [33] The liver diseases of lipodystrophy: The long-term effect of leptin treatment
    Zadeh, Elika Safar
    Lungu, Andreea O.
    Cochran, Elaine K.
    Brown, Rebecca J.
    Ghany, Marc G.
    Heller, Theo
    Kleiner, David E.
    Gorden, Phillip
    JOURNAL OF HEPATOLOGY, 2013, 59 (01) : 131 - 137
  • [34] Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino-terminal heterozygous missense lamin A/C mutations
    Subramanyam, L.
    Simha, V.
    Garg, A.
    CLINICAL GENETICS, 2010, 78 (01) : 66 - 73
  • [35] Phenotypic gender differences in subjects with familial partial lipodystrophy (Dunnigan variety) due to a nuclear lamin A/C R482W mutation
    Araújo-Vilar, D
    Loidi, L
    Domínguez, F
    Cabezas-Cerrato, J
    HORMONE AND METABOLIC RESEARCH, 2003, 35 (01) : 29 - 35
  • [36] Long-term efficacy of nelfinavir, adverse events and lipodystrophy
    Daniels, E
    Clotet, B
    Clax, P
    Artega, C
    Nelson, M
    ANTIVIRAL THERAPY, 2004, 9 (06) : L57 - L58
  • [37] Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2;: MIM 151660)
    Lanktree, M.
    Cao, H.
    Rabkin, S. W.
    Hanna, A.
    Hegele, R. A.
    CLINICAL GENETICS, 2007, 71 (02) : 183 - 186
  • [38] Leptin Substitution in Patients With Lipodystrophy: Neural Correlates for Long-term Success in the Normalization of Eating Behavior
    Schloegl, Haiko
    Mueller, Karsten
    Horstmann, Annette
    Miehle, Konstanze
    Pueschel, Janett
    Villringer, Arno
    Pleger, Burkhard
    Stumvoll, Michael
    Fasshauer, Mathias
    DIABETES, 2016, 65 (08) : 2179 - 2186
  • [39] Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy
    Ebihara, Ken
    Kusakabe, Toru
    Hirata, Masakazu
    Masuzaki, Hiroaki
    Miyanaga, Fumiko
    Kobayashi, Nozomi
    Tanaka, Tomohiro
    Chusho, Hideki
    Miyazawa, Takashi
    Hayashi, Tatsuya
    Hosoda, Kiminori
    Ogawa, Yoshihiro
    DePaoli, Alex M.
    Fukushima, Masanori
    Nakao, Kazuwa
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (02): : 532 - 541
  • [40] Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy
    Kusakabe, Toru
    Ebihara, Ken
    Hirata, Masakazu
    Masuzaki, Hiroaki
    Miyanaga, Fumko
    Kobayashi, Nozomi
    Tanaka, Tomohiro
    Hosoda, Kmnori
    Ogawa, Yoshihiro
    DePaoli, Alex M.
    Fukushima, Masanori
    Nakao, Kazuwa
    DIABETES, 2006, 55 : A472 - A472
12345